Ariad gets patent covering mTOR inhibitors

By Elaine Rigoli

Tampa, Fla., Aug. 15 - Ariad Pharmaceuticals, Inc. has been issued a U.S. patent covering its mTOR inhibitors, including its lead cancer product candidate AP23573, and uses of these compounds to treat various cancers and to prevent reblockage at sites of vascular injury following stent-assisted angioplasty.

U.S. Patent No. 7,091,213 provides coverage through the year 2023, according to a news release.

Based on positive phase 2 efficacy data announced earlier this year at the American Society of Clinical Oncology annual meeting, the company said AP23573 is set to enter a global phase 3 clinical trial in patients with advanced sarcomas.

This new patent covers AP23573 itself and a family of small-molecule compounds structurally related to AP23573, as well as important medical uses of these compounds, such as treatment of various cancers including, for example, soft-tissue and bone sarcomas; prostate, breast, pancreatic, brain, lung and colon cancers; and lymphomas and leukemias.

Related patent applications are pending in the United States and major markets outside the United States, the release said.

Ariad is a pharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.